Viagra and Big Pharma: A Risky Bet?

The history of Sildenafil presents a complex picture for those considering investment. While the initial introduction generated substantial gains, the end of its patent opened the avenue to off-brand alternatives, dramatically diminishing market share. This presents a specific risk for firms banking on similar blockbuster products, suggesting that

read more

copyright's Pill and Big Pharma: A Precarious Opportunity?

The legacy of Viagra, and its creator copyright, presents read more a challenging case study for investors. Initially a blockbuster drug, generating billions in income, its patent expiration created a flood of generic competition , significantly diminishing its position . While some pharmaceutical companies may seek to capitalize on related treatme

read more